A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.


Updates from The Motley Fool

Latest updates on Celgene from Fool.com.  The Fool has written over 700 articles on Celgene.
3 Incredibly Cheap Biotech Stocks

Here's why AbbVie, Celgene, and Gilead Sciences are three of the least expensive biotech stocks a...

What Could Make Biogen Crash?

Celgene's about to report data on a promising new multiple sclerosis drug that could significantl...



Stock Performance

View Interactive CELG Charts
Sponsored by

Key Data Points

Primary metrics and data points about Celgene.
Current Price: $123.38
Prev Close: $123.22
Open: $123.72
Bid: $122.78
Ask: $123.38
Day's Range: $122.95 - $124.13
52wk Range: $94.42 - $127.64
Volume: 2,845,493
Avg Vol 4,038,610
Market Cap: $96B
P/E (ttm): 49.49
EPS (ttm): $2.49
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Celgene.
CAPS Rating 5 out of 5
 
2183 Outperform
77 Underperform
CAPS All Stars
 
444 Outperform
12 Underperform

How do you think Celgene will perform against the market?



You pick for Celgene is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Mark J. Alles, CEO

90% Approve

Based on 25 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Celgene.

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers